Latest Hotspot

European Commission Authorizes Roche's Alecensa as First Targeted Adjuvant Therapy for Early-Stage ALK-Positive Lung Cancer

14 June 2024
3 min read

Roche revealed that the European Commission has granted approval for Alecensa® (alectinib) monotherapy as an adjuvant treatment post-tumor resection. This approval is specifically for adult patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer who are at a high risk of recurrence.

👇Unlock in-depth information about this drug - its R&D Status, Core Patent, Clinical Trials, and Global Approval Status. Click on the image below and explore the latest data immediately.

Data obtained from the Phase III ALINA trial, which showed Alecensa achieving a remarkable 76% reduction in the likelihood of disease recurrence or death in patients with resected ALK-positive NSCLC, bolstered the marketing authorisation submission.

"For the first time, individuals in Europe who have undergone surgical resection for ALK-positive NSCLC have access to an ALK inhibitor, which can considerably lower the risk of disease recurrence or death," said Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer and Head of Global Product Development.

"Surgery alone may not suffice for early-stage ALK-positive NSCLC, as the high risk of recurrence continues to trouble patients about their future," remarked Professor Fabrice Barlesi, a thoracic oncologist at Paris Saclay University and CEO of Gustave Roussy Institute. "The ALINA study revealed an unparalleled and consistent benefit in disease-free survival across all stages of the disease."

Alecensa is the treatment of choice for patients with advanced ALK-positive NSCLC and has revolutionized outcomes for those afflicted by this illness. It is approved as a first- and second-line treatment in over 100 countries, with more than 94,000 patients treated with Alecensa in clinical settings. With its approval for adjuvant treatment, Alecensa could, for the first time, be crucial for resectable ALK-positive disease, addressing a significant unmet medical need.

Alecensa is a highly selective, CNS-active, oral treatment developed at Chugai, part of the Roche Group, Kamakura Research Laboratories, for individuals with non-small cell lung cancer whose tumors are ALK-positive. 

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

图形用户界面

描述已自动生成

According to the data provided by the Synapse Database, As of June 14, 2024, there are 2 investigational drugs for the ALK and RET target, including 34 indications, 16 R&D institutions involved, with related clinical trials reaching 122, and as many as 3130 patents.

Alectinib Hydrochloride targets ALK and RET. It has been approved for the treatment of a wide range of therapeutic areas and indications, with its first approval in Japan in 2014. The drug has received regulatory designations and has reached the highest phase of development, indicating its efficacy and safety for use in patients.

图形用户界面, 文本, 网站

描述已自动生成

Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 13
Pharma Frontiers: Daily Digest of Global Pharmaceutical News - Jun 13
13 June 2024
Jun 13th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.
Read →
FDA Approves Almirall's Klisyri® for Treating Actinic Keratosis on Face or Scalp
Latest Hotspot
3 min read
FDA Approves Almirall's Klisyri® for Treating Actinic Keratosis on Face or Scalp
13 June 2024
The FDA has approved Almirall’s Klisyri® (tirbanibulin) for treating actinic keratosis on facial or scalp areas up to 100 cm².
Read →
Lilly's Tirzepatide: Over 50% See Fibrosis Improvement and MASH Resolution After 52 Weeks
Latest Hotspot
3 min read
Lilly's Tirzepatide: Over 50% See Fibrosis Improvement and MASH Resolution After 52 Weeks
13 June 2024
Lilly's tirzepatide outperformed placebo in resolving MASH, and over 50% of patients showed fibrosis improvement after 52 weeks.
Read →
New HBV-targeted TCR T Cell Therapy (SCG101) Shows Improved Survival in Liver Cancer: EASL Conclusion
Latest Hotspot
3 min read
New HBV-targeted TCR T Cell Therapy (SCG101) Shows Improved Survival in Liver Cancer: EASL Conclusion
13 June 2024
EASL Conclusion Session Emphasized Novel Clinical Data on Unique HBV-targeted TCR T Cell Therapy (SCG101) Demonstrating Enhanced Survival Rates in HBV-linked Liver Cancer.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.